Study to assess the tolerability and efficacy of AMG 145 in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.

Registry ID

EUCTR2011-001529-26

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Amgen Inc

Start date

2011-07-15

Last update

2026-08-16

Conditions

• Hypercholesterolaemia

Summary

To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145, compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic subjects unable to tolerate an effective dose of a HMG CoA reductase inhibitor.

Locations

• , , Sweden
• , , Finland
• , , Denmark
• , , Belgium
• , , Spain

Related clinical trials

• A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
• An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia
• Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
• Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
• LATAM LOWERS LDL-C

View on source registry